GlobeNewswire by notified

Strong results for 2022 and additional progress anticipated for 2023

Share

Based on the preliminary and unaudited income statements from the Group businesses, Schouw & Co. currently estimates its consolidated revenue for 2022 at approximately DKK 32.6 billion, as compared with the most recent guidance of DKK 30.1–32.0 billion, while consolidated EBITDA is estimated at about DKK 2,280 million, as compared with the guided range of DKK 2,090–2,260 million.

In particular, BioMar and GPV are reporting higher-than-expected revenue and EBITDA for the fourth quarter. Among the Group’s other portfolio companies, HydraSpecma, Borg Automotive and Fibertex Personal Care are reporting earnings in the upper half of their most recently announced guidance ranges, whereas Fibertex Nonwovens is reporting earnings at the lower end of the anticipated range.

BioMar’s acquisition of shrimp feed manufacturer Viet-Uc and Borg Automotive’s acquisition of trading company SBS Automotive in 2021 were both based on earnout models that will be recalculated as part of the year-end reporting. Preliminary calculations indicate that the recalculations may increase the Group’s net financing costs for 2022.

Schouw & Co. expects to maintain a high level of business activity in 2023 despite the persistent and significant market uncertainties. To this should be added the full-year effect of the EMS business acquired in October 2022 for the purpose of combining it with GPV, and the full-year guidance also includes the contribution from HydraSpecma’s acquisition of the Wind Division of Ymer Technology effective on 1 February 2023.   

As a result, Schouw & Co. expects to generate revenue of approximately DKK 36-38 billion and EBITDA in the range of DKK 2,350–2,650 million in 2023. As always, however, changes in prices of raw materials and foreign exchange rates may rather substantially impact the consolidated revenue without necessarily having a notable effect on earnings.

In its annual report for 2021, Schouw & Co. announced a long-term ambition to grow consolidated revenue, including from acquisitions, to more than DKK 35 billion with EBITDA of more than DKK 3 billion by the end of 2025. Recent acquisitions completed have contributed significantly to achieving this ambition, and the very high rate of inflation on prices of materials have triggered a significant revenue increase. As a result, the revenue ambition would now logically be around DKK 40 billion, while the EBITDA ambition remains for EBITDA of more than DKK 3 billion by the end of 2025.

Schouw & Co.'s 2022 Annual Report is scheduled for release on Thursday, 3 March 2023.

Aktieselskabet Schouw & Co.

Jørgen Dencker Wisborg, Chairman of the Board of Directors
Jens Bjerg Sørensen, CEO, tel. +45 86 11 22 22

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Ecorobotix Develops New Crop Algorithms for its AI-Powered Software7.5.2024 11:00:00 CEST | Press release

YVERDON-LES-BAINS, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- Ecorobotix, a sustainable Swiss Agtech firm, active in the field of AI-based weeding, proudly announces the ongoing development of its newest AI software algorithms, now available as “beta versions” for testing by Ecorobotix clients. These new algorithms mark a significant advancement in crop compatibility, offering new application possibilities for the ARA ultra-high precision sprayer. Which new crop algorithms are under development? Dicots in wheatCarrotsVolunteer potatoes in chicoryDock + ThistleCottonSoy Clients with an ARA sprayer can access these crop algorithms free of charge for a limited time. New clients in 2024 can also benefit from this opportunity. Clients interested in testing these algorithms are encouraged to reach out to the Ecorobotix sales team to update their ARA. Among the algorithms, the carrot algorithm stands out as particularly robust, already garnering praise from early adopters, with recent feed

DSV, 1106 - SHARE BUYBACK IN DSV A/S7.5.2024 09:53:54 CEST | Press release

Company Announcement No. 1106 On 24 April 2024, we initiated a share buyback programme, as described in Company Announcement No. 1104. According to the programme, the company will in the period from 24 April 2024 until 23 July 2024 purchase own shares up to a maximum value of DKK 1,000 million, and no more than 1,700,000 shares, corresponding to 0.79% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Trading dayNumber of shares bought backAverage transaction priceAmount DKKAccumulated trading for days 1-3145,0001,013.69146,985,0504:29 April 202475,0001,014.7176,103,2505:30 April 20247,0001,002.427,016,9406:1 May 20249,680993.049,612,6277:2 May 20247,320990.197,248,1918:3

Coloplast Finance B.V. - Interim Financial Report, H1 2023/247.5.2024 09:51:03 CEST | Press release

H1 2023/24 Interim financial results, H1 2023/24 1 October 2023 - 31 March 2024 Coloplast delivered a solid Q2 with 8% organic growth and an EBIT margin1) of 27%. Reported revenue in DKK grew 9% with 4%-points contribution from Kerecis (underlying growth of around 35%), partly offset by currencies. Organic growth rates by business area: Ostomy Care 7%, Continence Care 8%, Voice and Respiratory Care 13%, Advanced Wound Care 8% (Advanced Wound Dressings 8%) and Interventional Urology 5%.Continued good momentum in Chronic Care. Ostomy Care growth was driven by broad-based contribution from Emerging markets and Europe, compensating for lower growth in the US which was held back by order phasing and now expected to be H2 weighted. Continence Care growth was driven by intermittent catheters, including good contribution from LujaTM. Voice and Respiratory Care had a strong Q2, driven by double-digit growth in both laryngectomy and tracheostomy.Growth in Advanced Wound Dressings was broad-based

HiddenA line styled icon from Orion Icon Library.Eye